Tagged with A

Finnegan Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently. Can you provide what the initial impetus was to enter China as well as the operations here since 2008? As…

Venturepharm Venturepharm is the most diversified company we’ve seen, throughout many verticals, taking a full-service plus model from venture capital, merchant banking, CRO, CMO, CSO, compound partnering to royalty sharing. That’s quite broad; what exactly is Venturepharm? The company is centred around our flagship CRO/CMO/CSO, and our positioning is similar to…

Hooker Cockram - China Hooker Cockram is a well established company with an, impressive and rich history. Could you give us some background on both your operations in Australia and your operations in China since 1993? Hooker Cockram is Australia’s oldest construction company, in existence for 149 years. For 125 years, the firm was…

Biotech Pharmaceutical Co Ltd Could you please introduce the history and main characteristics of Biotech Pharmaceutical? Biotech Pharmaceutical was established in the year 2000, so we are a relatively young company for biopharmaceutical products by Chinese standards. However, we were the first company in China to discover, develop, manufacture and market monoclonal antibodies. Before…

The Balloch Group What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a masters thesis on China. This was during the Cultural Revolution so it wasn’t easy to come to China in those…

Covance China You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for about 14 years, which was the longest phase of my career. I have a strong passion for drug development –…

China MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps in the country. You just arrived in China in February. The country managers we’ve met have all been here for…

China Medicinal Biotech Association (CMBA) Could you please give us a brief introduction on CMBA? First and most obviously for new arrivals to our office, since 2011 we have changed locations, making it more convenient for companies to come here and benefit from the opportunities we can provide our members. CMBA’s membership now totals 205…

Beaufour IPSEN China Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you to the pharmaceutical industry? I have a very long personal history with China, starting back in my student days. I…

Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…

Maver Maver has an impressive track record in developing and commercializing blockbuster products for the Chilean market, such as Tapsin and Disfruta, which today are the #1 brands in their categories. What would you say has been your recipe for success? I believe our success is based on our targeted marketing…

Luye Pharma What was the transition like from academia into entrepreneurship and what challenges did you face in beginning this company? I realized during this period in the late 1980s that there were no local Chinese companies doing what I wanted to do at the time so I saw there was an…